News

AlvioLife® Receives License for Respiratory Support Claims from Health Canada

August 31, 2020
PLT Health Solutions Receives License for Respiratory Support Ingredient from Health Canada

MORRISTOWN, NJ 31 August 2020 – PLT Health Solutions, Inc. announced that it has received a license from the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada to market its ingredient AlvioLife® to support respiratory health in Canada. AlvioLife® is a proprietary composition of extracts of Boswellia serrata gum resin [standardized to 30% 3-O-acetyl-11-keto-ß-boswellic acid (AKBA)] and Aegle marmelos dried fruit, designed to support a respiratory health. Published clinical work has shown that it can help improve overall respiratory health, maintain clear airways, help against environmental exposure and soothe respiratory tissues.

In Canada, the approved claims include:

  • AlvioLife helps to support lower respiratory tract health
  • AlvioLife helps to support lower respiratory tract health that includes the bronchial tubes and the lungs’ health

According to Dr. Barbara Davis, Head of Clinical and Regulatory Sciences for PLT Health Solutions, the granting of an NHP license by Health Canada is a significant milestone for AlvioLife, both because it opens up the Canadian market for this unique ingredient and for what it says about the science that supports the AlvioLife.  “Respiratory health is at the top of everyone’s minds these days. AlvioLife is an interesting ingredient both as a standalone but also as a compliment to immune support ingredients,” she said. “The anti-inflammatory effects, particularly 5-lipoxygenase (5-LOX) inhibition by AKBA and quince fruit, are responsible for its effectiveness in supporting respiratory health. Accumulating and significant evidence suggests that 5‐LOX has profound influence on the onset and progression of airway inflammation,” she added.

Clinical Study on Respiratory-Impaired Individuals

A 56-day, randomized, double-blind placebo-controlled clinical trial was conducted to evaluate the efficacy and safety of  200 mg/day AlvioLife in participants with respiratory issues.[i]  Statistically significant improvement was observed for several parameters of respiratory health in study participants taking AlvioLife compared to those receiving placebo.  Response to environmental stimuli and breathing scores were significantly better in the AlvioLife group compared to the placebo group.  Peak Expiratory Flow (L/min) was significantly improved on day 56 in the AlvioLife group compared to the placebo (p<0.05) and Expiratory Volume 1 (FEV1) was improved on day 56 in AlvioLife group, but not in the placebo group. Quality of life issues were also examined.  Both activity limitation and emotional function scores were significantly improved on day 14, and further improved on days 28 and 56, compared to the placebo group.

 
[i] Yugandhar P, Rao KM, Sengupta K. A novel herbal composition containing extracts of Boswellia serrata gum resin and Aegle marmelos fruit alleviates symptoms of asthma in a placebo controlled double-blind clinical study. Phytother Res. 2018;32(1):140-150. doi:10.1002/ptr.5963

About PLT Health Solutions

Headquartered in Morristown, NJ, USA, PLT Health Solutions is a trusted discoverer, developer, and marketer of high-quality, scientifically-supported ingredients that enhance health and functionality. As a leading ingredients innovator, PLT’s global network of strategic partnerships provides unique access to impactful solutions. By delivering an unsurpassed mix of expertise, resources, and service, PLT is committed to helping both its strategic partners and valued customers grow

LEARN MORE ABOUT ALVIOLIFE HERE